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Intracranial atherosclerosis was traditionally believed to carry a risk of stroke of 8% to
22% per annum. The annualized stroke rate in the recent stenting and aggressive medical
management for preventing stroke in intracranial stenosis (SAMMPRIS) trial medical man-
agement arm was 12.2%. This trial was halted due to excessive periprocedural events in
the stent arm. This stroke rate is still unacceptably, high and a treatment strategy is still
needed. SAMMPRIS has no bearing on angioplasty alone. Angioplasty alone has always
been our primary intervention for intracranial atherosclerosis and remains so to this day
due to its relative simplicity, low complication rate, and efficacy. We have, however, made
adjustments to our patient management regimen based on the results of SAMMPRIS.
This paper outlines our current patient selection, procedural technique, and post-procedure
management.The complications we have encountered while developing our technique are
described along with how to avoid them and how to manage them. Our most recent results
(since previous publications) are also discussed.
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INTRODUCTION
The results from the completed warfarin versus aspirin for symp-
tomatic intracranial disease study (WASID) demonstrated that the
rate of subsequent stroke was 18% in the first year for patients with
symptomatic [transient ischemic attack (TIA) or stroke] stenoses
of ≥70% on “best medical therapy” (1, 2). The annualized stroke
rate in the medical arm of the recently published stenting and
aggressive medical management for preventing stroke in intracra-
nial stenosis (SAMMPRIS) was 12.2% (3, 4). This improvement
from WASID was achieved by utilizing aggressive medical man-
agement that included dual antiplatelet therapy with intensive
management of vascular risk factors combined with aggressive
lifestyle modification (3, 5). Even so, the subsequent 12.2% stroke
risk is still unacceptably high. Therefore, a treatment strategy is
still needed.
The SAMMPRIS trial was prematurely stopped due to exces-
sive periprocedural events in the stent arm. These results, however,
have no bearing on the procedure of angioplasty alone and the
associated risks and benefits, nor does SAMMPRIS have implica-
tions concerning the much simpler procedure utilizing balloon-
mounted stents. The failed stenting of symptomatic atheroscle-
rotic lesions in the vertebral or intracranial arteries (SSYLVIA)
trial examined balloon expandable stents; all 30-day complica-
tions were in locations not recommended by the authors (6). The
Vitesse intracranial stent study for ischemic therapy (VISSIT) trial
also did not incorporate the patient selection described here but
final results are not known; the trial was stopped prematurely (7).
Angioplasty has always been our primary intervention for
intracranial atherosclerosis and remains such to this day due
to its simplicity, low complication rate, and proven efficacy.
Following SAMMPRIS, however, we adjusted our overall patient
management regimen, as we will highlight below.
METHODS: CURRENT PRACTICE
PATIENT SELECTION
All patients presenting with transient ischemic attack or stroke
undergo cross sectional imaging [computed tomography (CT)
or magnetic resonance imaging (MRI)], with vascular studies
[CT angiography (CTA), MR angiography (MRA)]. Patients with
intracranial lesions thought to be the cause of the presenting
event (>70% stenosis by North American symptomatic carotid
endarterectomy trial (NASCET) criteria or<1 mm residual lumen
in the artery supplying the affected territory) are placed on maxi-
mal medical therapy as utilized in SAMMPRIS (3, 5). This is man-
aged by the neurologist (and cardiologist if the patient is under
the care of one) and is adjusted as needed to address each patient’s
specific condition and risk factors. Only patients who continue
to have symptoms on maximal medical therapy are considered
for endovascular therapy. Patients with incidentally discovered
asymptomatic lesions are considered for endovascular therapy
only if they have a high-grade stenosis (>70% and/or <1 mm
residual lumen) and require major surgery such as coronary artery
bypass grafting.
RATIONALE FOR TECHNIQUE
Our technique and its rationale evolved over the first decade of our
experience (~1990–1999) and have been described (8). A primary
goal in the development of any procedure is to minimize peripro-
cedural complications. In this instance, this was further driven by
the belief that complications could outweigh any minor benefit for
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stroke prevention, later confirmed by SAMMPRIS (4). Observa-
tions led to certain conclusions: (a) procedural simplicity fosters
procedural success, (b) excessive or rapid stretching of the vessel
leads to intimal damage (8), (c) selecting a balloon approaching
the size of the vessel more frequently leads to dissection, (d) inti-
mal damage can lead to acute or subacute thrombosis, occlusion
and/or stroke (8–10), and (e) intimal dissection leads to recur-
rent stenosis (10). It was, and is, our belief that the diseased vessel
lacks flexibility and is more fragile and brittle. This fact led us to
the analogy that this diseased vessel is like old leather: tough and
easily cracked. Very slow stretching seemed to reduce cracking.
Past attempts to achieve a nearly normal vascular channel
resulted in complications. While excellent post-angioplasty images
might be obtained, important perforators have been sheared off
even without visible dissection. This problem has been observed
not where plaque is located (where the wall is thick and tough)
but rather in normal areas of the wall opposite the plaque (where
the wall is thin). This result could possibly be due to various lay-
ers of the vessel wall (intima, media, etc.) stretching at differing
rates or in different directions, thus, leading to occlusion of the
trans-wall microvascular channels. “Snowplowing” of plaque into
(or onto) a perforator is a serious consideration but is rare in our
observations.
PRE-PROCEDURAL MANAGEMENT
Diagnostic cerebral angiography is generally performed as a sepa-
rate procedure in order to assess collateral flow and hemodynamics
as well as to plan the intervention. It also allows a more accurate
estimation and discussion of the risks and benefits of the pro-
cedure for that specific patient. Treatment options and timing
are discussed with the patient and family. The potential use of
“off-label” devices is explained. In general, patients continue to
receive all medications until endovascular treatment except when
contraindicated; the exception to this would be for the isolated
posterior (vertebrobasilar) circulation. Stenoses in an isolated
posterior circulation can cause secondary systemic hypertension
in an effort to perfuse the brainstem. When normal perfusion
is restored, the blood pressure can drop precipitously. We hold
the blood pressure medications on the day of the procedure for
patients undergoing treatment in an isolated posterior circulation.
Reperfusion hypertension can lead to hemorrhage, however, and
continuous close observation is required after reperfusion in case
the blood pressure needs to be acutely lowered.
PROCEDURE
General
All procedures are performed under general anesthesia. It is dif-
ficult or impossible to perform the entire procedure with the
necessary finesse while having even minor patient motion; even-
tually there will be a problem. The majority of procedures are
performed via a common femoral artery approach. Distal ver-
tebral and/or basilar artery angioplasties/stents are occasionally
performed via an ipsilateral brachial artery approach if there is
access difficulty from a femoral approach.
Guide catheter
The position and stability of the neurointerventional guide
catheter is critical. Every effort should be made to place the tip
as close as possible to the lesion in the intracranial portion of the
internal carotid artery (ICA) (typically petrous), or the level of C1
or C2 in the vertebral artery. Lack of safe, stable, and adequately
distal position can “make or break” the procedure. A distal posi-
tion of the guide catheter will help ensure a stable platform for
delivery of the microcatheter/balloon and facilitate navigating the
lesion with the necessary finesse. Once the working catheter and
microguidewire are outside the guide catheter, they will take the
outside track in all curves, thus, displacing the vital vectors of force.
Once vectors are displaced, all friction exponentially increases and
the “memory” in the shaft of the microguidewire can produce
stored energy while torquing or steering. Distal microguidewire
and catheter manipulation no longer have finesse and are more
unpredictable. This distal guide catheter position will also simplify
delivery of a stent if needed.
Modern guide catheters have significantly improved our ability
to position the tip where necessary [e.g., Neuron (Penumbra, Inc.,
Alameda, CA, USA)]. Sometimes, however, a high position of the
guide catheter is not enough to ensure its stability due to markedly
tortuous proximal vessels. In these patients we advise the use of
tri-axial system [e.g., a Shuttle sheath (Cook Inc., Bloomington,
IN, USA)] through which a neurointerventional guide catheter is
placed intracranially (e.g., Neuron). Indeed, a tri-axial system is
now frequently employed (see Distal Tri-Axial Guide Catheter).
Telescoping distal access technique. If a carotid or vertebral
artery is particularly tortuous and catheterization with a stan-
dard wire is difficult or dangerous, we recommend performing a
telescoping access maneuver. Place the guide catheter proximal to
the difficult access and load a microcatheter and microguidewire
through a Y-connector. Select the vessel with a microguidewire and
navigate the tortuous curves, following with the microcatheter.
Once the microcatheter is well downstream, remove the microgu-
idewire and replace with a stiff microwire, either regular length
or exchange length. If the guide catheter itself is made coaxial
by the use of an inner distal access catheter [DAC (Stryker Neu-
rovascular/Concentric Medical, Mountain View, CA, USA)], the
stiffer exchange-length microwire can provide sufficient stability
to allow advancement of the distal access catheter followed by the
guide catheter. In this way, there is progressive straightening of
the vessel and never a large wire or blunt face of a guide catheter
snowplowing on the vessel and potentially causing a dissection.
Proximal tri-axial stabilized guide catheter. If there is a con-
genitally small vertebral artery, a sheath (e.g., 8 Fr Shuttle) can be
positioned in the subclavian artery proximal to the vertebral artery
origin. First select the axillary artery and position an exchange
wire [e.g., Connors exchange wire (Cook Inc.,)] with the tip dis-
tally in the axillary artery. Follow with the Shuttle sheath into the
subclavian artery and then replace the exchange wire with a stiff
exchange-length microwire [Hi-Torque Sparatcore (Abbott Vas-
cular, Abbott Park, IL, USA)] and secure this wire. The sheath can
then be withdrawn to a point just proximal to the vertebral artery
without fear of the guide catheter buckling into the aorta.
Distal tri-axial guide catheter. Many times it is necessary to pro-
vide stiffer support for the guide catheter. This can be performed
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by placing a long 8 Fr. sheath (e.g., Shuttle) into the carotid artery
and then advancing the guide catheter through the sheath. For
shorter patients, and depending upon where the tip of the guide
catheter is to be placed, a 60–80 cm sheath [e.g., Raabe (Cook
Inc.,)] is placed so that the guide catheter has adequate length
distal to the sheath.
Intraprocedural and periprocedural medication
Oral dual antiplatelet medication is mandatory before all cases.
With modern medications, this should never be an issue. Tra-
ditionally, aspirin (325 mg non-coated) and clopidogrel have
been utilized, although newer antiplatelet agents are also utilized.
Platelet inhibition is usually assayed when a patient fails medical
therapy; it is increasingly assayed on a routine basis. When a patient
is on a single antiplatelet agent prior to an elective procedure, the
second agent is started and platelet inhibition is assayed prior to
the procedure.
Intraprocedural anticoagulation (e.g., heparin, bivalirudin) is
always administered. With the advent of modern antiplatelet med-
ications, rarely is there a need for rescue with GP IIb/IIIa inhibitors
such as abciximab. The exceptions to this rule include emergent
procedures, such as angioplasty performed in the course of acute
stroke therapy, where a GP IIb/IIIa inhibitor might be necessary
for bridging until oral antiplatelets take effect. This is typically nec-
essary for clopidogrel, but aspirin is effective within minutes when
administered orally or rectally. Other newer antiplatelet agents
(e.g., ticagrelor) are also more rapidly effective than clopidogrel.
When any GP IIb/IIIa inhibitor is used, a very dilute mixture
is infused very slowly in order to bathe the thrombus over an
extended period: minutes, not seconds. While a systemic dose can
be infused rapidly (and thus recirculate to achieve benefit), a local
intra-arterial dose is very effective without producing systemic
effects when administered in this manner.
Any reperfused territory can be susceptible to reperfusion hem-
orrhage, but isolated vascular territories (those without circle
of Willis collaterals) are particularly susceptible. For hyperten-
sive emergencies, it is mandatory that intravenous (IV) labetalol
bolus (not nicardipine drip) be immediately on-hand if needed.
Labetalol (a mixed alpha/beta adrenergic blocker) is specifically
intended for use in hypertensive crises (start with 10 mg IV bolus
followed by 20 mg every 2–5 min up to 200 mg.). On the other
hand, nicardipine (a calcium ion influx inhibitor/“slow channel”
blocker or calcium channel blocker) is only intended for infusion
and is safe but slow even as a bolus (effects take several minutes).
Choice of balloon
Angioplasty alone is almost always our intention. Occasionally
we will choose primary stenting (see below). Secondary stenting
is only performed in rare circumstances such as when the lesion
does not respond to repeated angioplasty, there is unacceptable
rebound stenosis (return to the pre-angioplasty degree of stenosis
or worse), or there is a resultant large dissection.
Most balloons have coronary indications, as do the balloon
expandable stents we primarily use. The shortest balloon that will
comfortably cover the length of the stenotic segment is chosen,
typically 9 or 10 mm. A longer balloon will typically straighten the
vessel, thus, stretching the shorter length of the inner curvature
and possibly causing a dissection. The balloon diameter is under-
sized relative to the vessel diameter by 0.25–0.5 mm as previously
described (8–11). In most cases, an over-the-wire system is utilized
due to superior tracking ability, more sensitive “push–pull,” and
appreciably more accurate control of the microguidewire when
compared with a rapid exchange (monorail) system.
With modern tools and utilizing first-pass over-the-wire bal-
loon technique, crossing a lesion is rarely a problem. Rapid
exchange balloon systems perform far worse than over-the-wire
systems for this challenge. Due to the fact that the wire is external
to the shaft of the catheter, it will follow a different path from
the catheter. This results in the development of excessive friction
as well as stored energy. The wire will be forced to reenter the
catheter and the combination of these factors will impede subtle
and accurate microguidewire tip movement. We strongly believe
that over-the-wire systems are more suitable for distal intracranial
work. A monorail system can be utilized in the setting of proximal
lesions (e.g., petrous or cavernous segment of the ICA or distal
vertebral artery) and relatively straight vessels.
Choice of stent
Multistep self-expanding stents are rarely used unless necessary to
tack down a large dissection (a rare occurrence with the defined
technique). This is due to the fact they these are indeed “multistep”
and require perfect technique every time. Two pairs of hands are
required, both of which need to work in concert. In addition, it
may be very difficult to safely re-cross self-expanding stents.
We now make occasional exceptions and perform primary
stenting for specific locations. These would include the bare seg-
ments of the distal vertebral artery, the pre-ophthalmic carotid
artery or, rarely, the proximal basilar artery. For instance, a stent
might be chosen for a large eccentric plaque in a large vessel (proxi-
mal basilar artery) or for a larger artery in a segment known to have
no perforators (distal vertebral artery proximal to the posterior
inferior cerebellar artery). Stents are always the shortest available
(8 mm if possible) and, of course, undersized. Even so, these stents
are frequently hanging free in the vessel at one end of the plaque
or the other with no clinical implications (free portions of stents
are frequently present in vertebral origin or carotid stenting).
Procedural technique
Immaculate preparation of the balloon is mandatory if you wish
to actually see the balloon. When inflating a balloon, the first thing
that actually enters the balloon will be air and this must be essen-
tially 0. A fully inflated 2 mm× 10 mm balloon will hold<0.06 ml
of fluid. If any appreciable amount of air is present, the proce-
dural damage might be done before you even see the balloon. Last
second preparation with instant vacuum occasionally results in
almost no contrast whatsoever (all air) in these micro-balloons.
Therefore, we prepare these tiny balloons before the procedure
with repeated vacuum syringes/stopcocks and replacing all air
with contrast before advancing into the brain. A short microtube
(30 cm) or luerlock can remain in place attached to the balloon
port that can then be used to inflate the balloon after it has reached
final position.
With the recommended technique, true inability to access the
lesion is now rarely a cause of procedural failure (our technical
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success rate over the past 7 years has been 100% in 121 patients).
Utilizing modern devices, most cases are performed with a first
intention direct approach with an over-the-wire balloon catheter
and microguidewire [e.g., Transcend.014 EX Platinum (Stryker
Neurovascular, Fremont, CA, USA)]. Accessing the lesion is a two-
step process. The first step is simply getting the balloon to a point
just proximal to the lesion. This is accomplished with task-specific
roadmaps for aid in selecting the intracranial site just proximal
to the stenosis. For instance, traversing the petrous and cavernous
carotids requires different views and less magnification than those
for the highly important part of actually traversing the middle
cerebral artery stenosis for the first time. Once the proximal posi-
tion has been reached, repositioning the image intensifiers will be
necessary. One plane will be chosen with maximum magnification
for the absolute best view of the stenosis itself (at right angles) with
minimal bone overlap. The other plane is used for overall supervi-
sion of the procedure. The field of view must include a good view
of the stenosis and an optimal view the targeted location for the
distal tip of the microguidewire. Being able to see the distal tip of
the microguidewire for the entire procedure is mandatory.
Certain lesions (carotid siphon, basilar artery) can be shelf-like
and on the outer rim of a sharp turn. Simply traversing the stenotic
region is NOT the goal. If the microguidewire crosses the stenosis
within the plaque, balloon inflation will then displace the plaque
into the vessel lumen and make the situation worse or critical.
It is imperative to avoid dissection of the plaque when crossing
it. Finesse, patience, a stable and distal guide catheter position
and technical skill are all necessary to traverse particularly irreg-
ular or eccentric stenosis. For difficult lesion access, the use of
a tight J-shaped curve may be helpful by keeping the microgu-
idewire in the central lumen. The wire tip can safely choose its
path better than the operator. If primary direct approach angio-
plasty is not possible safely, or if secondary stenting is to be
performed, a low-profile microcatheter designed for intracranial
use may be advanced across the stenosis over the microguidewire.
The microguidewire is then replaced with a microexchange wire
[e.g., X-Celerator (Covidien/ev3 Neurovascular, Irvine, CA, USA)]
after placing a very tight (~2 mm) P-shaped curve at the tip of the
exchange wire to more safely allow for the inevitable to-and-fro
motion of the wire tip for the next 30 min (at least). The balloon
or stent is advanced over this wire.
Experience has taught us that inflation needs to be extremely
slow with a goal of about 1 min to reach 1 atm and 4 min for com-
plete inflation. Self-control is very important; one way to accom-
plish this is to very slowly inflate the balloon to <1 atm and/or
when the balloon can be barely seen, set the indeflator down, and
walk away. Even when stenting is performed, minimizing under-
lying vessel wall damage is still the goal since intimal damage can
cause secondary intimal hyperplasia with resultant restenosis (9,
10). Therefore, we still inflate very slowly but admittedly faster
than with angioplasty.
Observation period
After angioplasty or stenting is performed, the balloon/delivery
catheter is withdrawn proximal to the stenosis, leaving the microgu-
idewire (or microexchange wire if used) across the stenosis to preserve
access. Intraprocedural observation of the angioplastied/stented
site is performed to observe for three possible sequelae: rebound
stenosis, significant dissection, and/or acute/subacute thrombosis.
With the use of pre-operative dual antiplatelets, the latter has been
essentially non-existent as opposed to early experience when sub-
acute appearance of clot was not infrequently observed. Follow-up
angiography is performed twice within 20–30 min to ensure the
absence any of the complications mentioned above; there is always
delayed observation. If rebound stenosis is observed, prolonged
repeat angioplasty with the same balloon (possibly to a higher pres-
sure and longer interval) is initially performed. Be aware that this
can then result in the very complication to be avoided: dissection.
Be careful and judicious. Rarely, a larger balloon may be used or a
stent might be tried,although it is best to avoid (a) catheter/balloon
exchanges, and (b) use of a secondary stent (both thought to be
primary causes of the periprocedural complications in SAMM-
PRIS). This is almost always possible. Even self-expanding stents
are clumsy intravascular instruments in comparison to angioplasty
alone. If a large dissection is observed with subsequent thrombus,
abciximab may be used along with patient observation to avoid
use of a stent. Even clearly visible severe dissections typically heal
if adequate flow is maintained for an hour.
If occlusion or dissection progresses and rescue stenting
becomes necessary, the necessity of maintaining distal microwire
position is clear. If necessary, the working catheter/balloon can be
advanced safely back through the lesion over the microguidewire
and a microexchange wire can then be placed. The choice of a
rescue stent (balloon mounted or self-expanding) depends greatly
not only on the anatomy but also on personal skill and that of
your team. Most of these problems occur in short vessel segments
in curved arteries and necessitate a self-expanding stent but our
recent experience indicates that the need for a stent or exchange
technique is rare.
POST-PROCEDURE MANAGEMENT
A CT scan is obtained immediately after the procedure if there is
angiographic concern, or any time that a change in neurological
status raises suspicion of procedural complication.
The vascular territory downstream of the target lesion may not
have seen systemic pulse pressure in quite some time. In order to
prevent reperfusion/hyperperfusion hemorrhage strict attention is
paid to blood pressure with the goal of keeping the systolic pressure
within a specified low-normal range (110–140 mm Hg) utilizing
IV labetolol or nicardipine drip. (A single reperfusion hemor-
rhage inspires a lifetime of caution). As previously discussed, in
our experience the patients with the highest risk of reperfusion
hemorrhage (or headache) are those who had very poor collater-
als (pial or circle of Willis), resulting in an isolated territory. In this
circumstance the vascular bed will be maximally dilated.
Patients are initially managed in the intensive care unit. Once
stable, they are transferred to the stroke unit. Most patients are
ready for hospital discharge (or transfer to rehabilitation in the
case of patients presenting with an acute stroke) within 24 h of the
procedure. Discharge medications are discussed with the attend-
ing neurologist who will be following the patient. All patients are
discharged on dual antiplatelet therapy unless warfarin therapy is
required for another condition such as atrial fibrillation in which
case aspirin alone is added (81 mg/day).
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FOLLOW-UP
All patients are followed clinically 1–2 weeks after discharge. All
patients are evaluated with cerebral angiography 8 weeks after the
procedure. If the follow-up appearance is satisfactory, imaging is
repeated at 3 months, 6 months, 1 year, and then at yearly inter-
vals using CT or MR angiography. Dual antiplatelet therapy is
continued at least until stability is demonstrated on the 3-month
images. Any decision regarding a change to single antiplatelet ther-
apy is made in conjunction with the neurologist (and cardiologist
if applicable).
If a significant restenosis (>70%) is demonstrated at the time of
follow-up, the patient may undergo repeat angioplasty (or stenting
if necessary) even without recurrent symptoms (as per local pro-
tocol) and is then followed as described above. The rationale for
treating asymptomatic restenoses is twofold. WASID confirmed
that a certain percentage of patients will not have recurrent symp-
toms manifested by TIA but rather by stroke or death (1, 2)
and these patients have already failed a trial of maximal medical
therapy for this lesion. We have also learned that repeat angio-
plasty is extremely low risk with an event rate approaching 0
(none in a decade). Asymptomatic restenoses of lesser severity are
observed with repeat angiography and only treated if they became
symptomatic.
Whenever a patient experiences symptoms possibly related to
the treated stenosis, an MRI is obtained (or a CT if necessary)
and an angiogram is performed. Repeat angioplasty is performed
if indicated. Rarely, a lesion related to atherosclerotic plaque
is encountered that continues to develop significant restenosis
despite multiple interventions. In our early experience, some pro-
gressively stenotic lesions were observed that responded poorly to
primary and repeated angioplasty as well as to stenting. Indeed,
these behaved similarly to moyamoya disease but were not at the
ICA terminus. These stenoses were typically in a single location
and were usually found in the middle cerebral artery or supracli-
noid ICA. They had smooth gradually tapering edges not typical
of atheromatous plaque. These are currently thought to represent
a form of inflammatory obliterative vasculopathy, similar to moy-
amoya disease. We now identify these lesions in advance and do
not intervene but rather use maximum medical therapy, which for
us includes cilostazol (12). No matter the treatment, these have
a poor natural history. Encephaloduroarteriosynangiosis (EDAS)
can be performed if indicated.
COMPLICATIONS, HOW TO AVOID THEM, AND THEIR
MANAGEMENT
As discussed previously in the rationale for technique, we observed
early in our experience that excessive or rapid stretching of the ves-
sel and use of a balloon approaching the diameter of the vessel in
size lead to intimal damage; intimal damage can lead to acute or
subacute thrombosis, occlusion and/or stroke (8–10), and intimal
dissection leads to recurrent stenosis (10). The resultant changes
in technique have significantly reduced the incidence of compli-
cations. In current practice, if slightly excessive micro-dissection
is seen, it is usually associated with “hurried” inflation.
The complications associated with the phases of development
of our technique have been reported previously (8, 9). In current
practice, periprocedural complications (within 24 h) are rare and
minor. Specifically, the 30-day event rate over the past 7 years has
been 2.5% (3/121 procedures), all minor. One patient presented
with a symptomatic recurrent stenosis 27 days after angioplasty.
Another patient had a very resistant eccentric stenosis in the
cavernous ICA that required inflation of the balloon to 8 atm
pressure and had a resultant dissection, which was treated con-
servatively and was healed on the first follow-up angiogram. The
third patient had a transient neurological deficit of unclear etiol-
ogy that resolved within 24 h; MRI obtained at the time did not
reveal any acute findings.
GUIDE CATHETER PROBLEMS
All guide catheter problems should be avoidable; if there is doubt
as to sufficient positioning with sufficient support, withdraw, and
attempt another day. A final evaluation of the parent vessel and
guide catheter location should always be performed at the end of
the case. Thrombus forming around or in the guide catheter is
related to procedural technique. Simply observing distal flow dur-
ing injection does not indicate flow around the body of the guide
catheter itself; that is confirmed by watching run-off, not the con-
trast injection. The most serious problem, in-catheter thrombus, is
related to lack of constant adequate flush (or slight back-bleeding )
with resultant stagnant blood in the guide catheter lumen. The
final follow-up run will inject thrombus and reveal this situation.
PARENT VESSEL DAMAGE
Parent vessel damage is caused by poor guide catheter tip posi-
tioning, poor choice of guide catheter, initial manipulation, or
intraprocedural movement. Stable position in the petrous (or
more distal) ICA or C-2 vertebral artery level is recommended
but admittedly might be difficult. It is imperative to choose the
best guide catheter for the particular case in order to obtain a sta-
ble platform. The catheter tip will always be on an outer wall even if
it looks like it is not. A suitable tip location with adequate support
prevents the guide catheter for being forced to withdraw proxi-
mally, which could necessitate re-advancement into a high-tension
system. The tip should not be positioned in a curved segment of
the vessel where it will always be forcefully on an outer curvature
and could cause dissection related to movement produced by the
patient’s heartbeat and/or respiration. If dissection is significant,
stent placement may rarely be necessary. Dissections heal with the
medical management the patient is already on. Unless emergent,
we do not work through recently damaged intima associated with
a stent but rather let it heal and return at another date.
If spasm of the parent vessel is detected, the guide catheter
should be withdrawn to a more proximal (and comfortable)
position in the vessel and simply observed. While injection of
nitroglycerine might alleviate the vasospasm quickly (50 mcg/ml
of normal saline up to 100–200 mcg.) this is at the cost of sig-
nificant vasodilatation of the downstream capillary bed. Simply
waiting usually suffices and is particularly true in the case of acute
stroke.
VESSEL DAMAGE FROM THE DISTAL MICROWIRE TIP
It is important to use a suitable microguidewire designed for
intracranial use with a soft and safe tip (e.g., Transcend.014 EX
Platinum). Damage from the microguidewire tip typically occurs
during initial wire manipulation or during active treatment of
the lesion (balloon inflation). The single most hazardous event in
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every case is inadvertent movement of the distal microguidewire
(or microexchange wire) tip causing perforation. The distal tip of
the microwire must remain within the fluoroscopic field of view
at all times during the procedure in order to ensure that it does
not veer into an unseen small side branch where it has no room
to buckle, with resultant perforation. While small branch perfo-
rations can be tolerated occasionally, this might not be the case
when a patient is on dual antiplatelets and full anticoagulation. If
necessary, once the lesion is crossed with the balloon, the microgu-
idewire can be withdrawn and a tight P-shaped curve placed at the
tip before advancing it. If a microexchange wire is used, the same
curve should be placed at the tip.
The microwire tip should be advanced well downstream from
the tip of the balloon past the stenosis and carefully positioned in
a relatively straight segment of a vessel. In the anterior circulation
this might be the M-1 segment of the middle cerebral artery or
the M-2 segment (the inferior angular branch). Never intention-
ally place the microwire tip in the anterior division of the middle
cerebral artery. The “candelabra” branches of the anterior division
make sharp 180° turns in a distance of millimeters from the M-
1 bifurcation and the guidewire (no matter how soft) will easily
perforate at the bend rather than make the 180° turn in 3 mm. It
is mandatory to take the time to position the tip of the microwire
correctly and in the location recommended. If necessary, you can
withdraw the microwire and reshape the tip; another reason to use
an over-the-wire system.
After angioplasty, it is very important to maintain distal
microwire position and avoid recrossing the lesion, particularly
after manipulation. No matter how adept the operator believes
himself or herself to be, it is not possible to skillfully advance
a microguidewire through the center of the lumen of a newly
dilated vessel regardless of whether or not there is visible dis-
section. Trying to accomplish this can result in worsened vessel
dissection, perforation, or occlusion. If distal microwire position
is lost, it may be necessary to accept the angioplasty result and max-
imize efforts to prevent and treat thrombus rather than potentially
worsen the situation. Prolonged observation is usually sufficient.
Another attempt can be made several weeks later.
THROMBUS FORMATION AND DELAYED OCCLUSION AT THE SITE
In the early days of this procedure, delayed stroke (hours) was
thought to possibly be the result of delayed vasospasm. We now
understand that delayed stroke is due to delayed thrombus forma-
tion with or without progressive dissection leading to vessel occlu-
sion. This was formerly the most common potential complication
of this procedure. Delayed observation is therefore mandatory.
Exposed endothelial matrix is very thrombogenic. A small
amount of intimal damage is inevitable when performing angio-
plasty or stenting, but visible thrombus is rarely seen in present
practice. This is almost certainly due to the consistent use of
preprocedure dual antiplatelet therapy. Visible subacute platelet
clumping can be treated with GP IIb/IIIa inhibitors (e.g., abcix-
imab). A very dilute and slow intra-arterial infusion will be
vastly more concentrated than any serum level and will bathe the
thrombus for a prolonged period with better clinical results. For
abciximab, 5–10 mg in 30 ml injected over 5–10 min is usually
sufficient and will not give an appreciable systemic effect.
DISSECTION AT THE SITE OF ANGIOPLASTY
A small amount of vessel damage might be unavoidable. However,
the best solution for a true “macro” dissection (visible intimal
flap) is avoidance. The techniques of undersizing the balloon and
extremely slow inflation were developed to minimize this risk (9).
The rate of significant dissection and subsequent restenosis has
been very low (8).
If a hemodynamically significant dissection does occur, the
lesion is accessible, and the microwire still has distal position, a
stent can be placed as a last resort. With or without a stent, the
current dual antiplatelet therapy and intraprocedural anticoagu-
lation typically maintains patency in the vessel, allows the situation
to stabilize, and usually is sufficient.
EMBOLI
There are three principal causes of downstream emboli, all rare.
First, the guide catheter can produce thrombus (inside or out).
Second, thrombus that forms at the angioplasty site can migrate
downstream. Third, thrombus or plaque can be dislodged from
the original lesion. The use of dual antiplatelet therapy has greatly
reduced the incidence of emboli from this source. Thrombus at the
site of the original lesion is usually encountered in the setting of
a patient with recurrent or crescendo symptoms, presumably due
to unstable plaque, and who fails medical therapy rapidly. If there
appears to be thrombus present and it is necessary to continue
with the procedure, it is better to treat thrombus in situ rather
than downstream. Be patient and treat as described above.
Treatment of an embolus is dependent upon its composi-
tion. Acute thrombus is typically composed almost exclusively of
platelets and responds well to GP IIb/IIIa inhibitors. The embolus
will be relatively small and should migrate to a second- or third-
order vessel; the time for rescue can be prolonged in this setting.
If contrast reaches the thrombus, the therapeutic agent will also.
Clinically significant emboli are rare in recent practice.
REBOUND STENOSIS
Rebound stenosis is the major drawback of angioplasty with an
undersized balloon but this is not a complication. Purposely
undersizing the balloon will prevent major intimal damage as com-
pletely as possible. This process will, however, cause some lesions to
be inadequately dilated. A certain amount of damage may be nec-
essary to produce sufficient dilation, but an inadequate result that
must be retreated at a later date is preferable to a damaged vessel
leading to intimal flap or occlusion. Recurrent stenosis secondary
to intimal hyperplasia associated with healing of the angioplasty
site is the reason for early evaluation at 8 weeks after angioplasty
or stenting. In our experience, recurrent stenosis occurs very early
in the post-procedure period.
Intrinsic elastic recoil does not appear to be as great a problem
in intracranial lesions as in extracranial lesions such as the verte-
bral artery origin. Vessel geometry, however, can be a problem. The
bend of a vessel (e.g., the curve of the distal vertebral artery at the
skull base) is a poor location for effective angioplasty, and prone to
kinking after angioplasty. Stent placement in these locations can
also be problematic, but often produces a better result. This is a
typical location for primary balloon-mounted stent use.
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DISCUSSION
Clinical results have shown that modest angioplasty results pro-
duce satisfactory clinical results (8–11, 13, 14). A review of our
experience over the last 7 years reveals that 121 procedures were
performed. As noted above, there were three complications. Pri-
mary stenting was performed in 11 instances and secondary stent-
ing in 3. There was 100% technical success. There has only been
one patient who presented with a symptomatic recurrence, treated
successfully. We attribute these results mainly to the decrease in
significant dissection following angioplasty. Dissection has been
shown prospectively to be a statistically significant predictor of
not only stroke in the periprocedural period but also of restenosis
at the follow-up angiogram (10). These facts confirmed our obser-
vational impression and affirm our mantra of “avoiding dissection
at all costs.”
The complication rate of angioplasty alone in these different
papers consistently was <4.5% for major and minor compli-
cation combined at 1-year post intervention. This complication
rate for intracranial angioplasty provides a reasonable treatment
strategy for symptomatic intracranial atherosclerotic stenosis with
its attendant risk of at least 12.2% stroke/death within the first
year (1–4).
Concerning the issue of intracranial stenting in treatment
of symptomatic intracranial atherosclerotic disease (ICAD), we
believe that the available self-expanding stent technology has been
proved to be difficult to place without complications. Conversely,
we have found balloon-mounted stents to be simple to use, safe,
and effective when used in the recommended locations. We believe
that stenting, both self-expanding and balloon expandable, should
be reserved for particular situations.
In summary, experience has taught us much about the safe and
efficacious performance of intracranial revascularization. The key
points of our current technique, as discussed above, are as follows:
1. Careful selection of the guide catheter combined with patient,
skillful placement of the tip in the recommended distal location
is extremely important both for technical success and avoidance
of complications.
2. The shortest balloon possible should be chosen and the
diameter should be downsized relative to the vessel diameter.
3. Impeccable attention to detail with wire manipulation and
crossing of the stenosis is mandatory. Distal wire tip position-
ing is crucial. The distal tip of the microwire is the greatest
cause of periprocedural complications.
4. Excruciatingly slow balloon inflation is second only to submax-
imal sizing in importance for preventing dissection.
5. Secondary stenting should be avoided if possible.
CONCLUSION
Although aggressive medical management has decreased the inci-
dence of stroke associated with intracranial atherosclerotic steno-
sis, there is still a failure rate of >12% at 1 year. An important
role for endovascular intervention remains. Angioplasty alone
in carefully selected patients has repeatedly been shown to be
technically feasible. Dissection should and can be avoided with
the recommended technique. Studies have consistently demon-
strated angioplasty alone to provide clinical benefit for intracranial
atherostenosis better than stenting or medical management alone.
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